Development of CAPER peptides for the treatment of triple negative breast cancer.

Cell Cycle · 2020 · PMC7100886 · PMID 31931653

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

CAPER peptide HCC1.4 showed a trend in this direction, though it was not significant.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.